Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Denmark
Sweden
Finland
Norway
Latest
Trending
Followed

Oriola, Webcast, Q1'25

By Inderes4/29/2025, 7:00 AM
Oriola

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Dennis O'Neill
00:01 - 00:52

Good morning everyone, and a warm welcome to the Audio+ Q1 results webcast. My name is Dennis O'Neill, and I'm from Oriola's Investor Relations. With me today, I have our CEO, Katerina Gabrielson, and CFO Mats Danielson. After the presentation, we will open up for your questions, and please, you can already start to send in the questions through the chat. And as a reminder, we are also recording the webcast and it will be available on the website later today. And then if we go to the next slide, here is our customer disclaimer that we all should be aware of. And without further ado, I would like to hand over to Katerina.

Katerina Gabrielson
00:52 - 11:25

Thank you, Katerina. And this is the agenda for today. This is quite a traditional agenda that we have in these webcasts. We will start with the highlights, then move on to the operating environment segments. And then we will talk about the Financial Review before we come to the Q&A, starting then with the highlights of the first quarter. I'm really happy to be able to see that we have steady growth and progress towards the long-term goals that we have. The net sales in the first quarter of 2025 ended up at €447 million. It's a 19% growth. The organic growth is 8%. Since we still have the positive effect of a change in the ownership stock from consignment stock to ownership stock that we announced in quarter three 2024. Also, the sales margin improved; it increased to €41.3 million. And the sales margin is supported especially by the distribution segment. The adjusted EBITDA declined, though due to higher costs. And we'll come back to that a little bit later in this presentation. The reason is that I can see we have made good progress towards the long-term goals. We have customer satisfaction at an all-time high in both countries, and that is really something that we should benefit from for the future. During the quarter, we have also acquired MedInfo in Denmark. It's a small investment, but still, it's an important step for us to have a larger Nordic footprint in the advisory services. In Q1, we also received the final decision from the competition authorities regarding the sale of Svensk dos to Apotex. And this sale was completed on the 1st of April this year. And that has been a lengthy process, taking around one and a half years for us to finalize the ERP project. We announced a little bit more than a year ago, and that is proceeding according to plan. And we are getting closer to the first deployment that will happen in Sweden. So we will come back to that later on this year. Kronans Apotek, our joint venture company, has strengthened its market share in both the e-commerce sector and in physical pharmacies. We have double-digit growth, and we can also see that we are growing the market share in physical pharmacies, which hasn't happened for quite a while. That is the first time for quite a while. Um, we can also see that we have made major milestones in the integration at Kronans Apotek. For example, we have merged the legal companies into one company, and of course, there are still some integrations to be done. But we can also see that it is going to be easier to manage this company in the future. Then looking at the operating environment, what we can see really here is that consumer confidence has been weak during the first quarter. So let's see what's happening for the future in these areas. And of course, this is also affected by the current unstable geopolitical situation that we have. And we will not know exactly what will happen in this market. Of course we are more stable, but like any company, we are affected by what's happening with the tools and other things in the surroundings. The cost inflation has slowed down with more normalized energy and fuel prices. We also start to understand now where the salary costs will be for the coming years, since the union negotiations are nearing completion in both countries. Challenges in the availability of medicines are something that we have talked about quite a lot during this webcast in the last few years. There are still challenges in the market in Europe, and I can see that it's not worse, but it's not better either. And we can't see it like that. It will not be better for the coming months either. So this is something that we will continue to live with. Like we have said before, the value of the pharmaceutical distribution market has been growing, especially in Sweden. It has slightly declined in Finland, but in Sweden, we can really see that the value has been much stronger than in Finland. Then going to our different segments, the distribution segment, if you start with that one, which consists of the pharmaceutical goods that we are distributing for the pharmaceutical suppliers to pharmacies and also veterinarians, has been growing by 22% to €359 million. We can see solid volumes in Sweden and a weaker market in Finland. That is impacting the sales in this segment. Like I said before, we have a change from the consignment stock to the ownership stock in quarter three, and that is still positively impacting this segment, which means that organic growth landed on 8%. Here we can see that net sales growth impacted profitability, along with a favorable product mix. We can also see that the OpEx has increased in this segment, and that's due to the customer ordering patterns we have. We are really dependent on a stable ordering pattern from our customers. And if we don't get a stable ordering pattern, that is affecting the cost quite fast. And in this time of the year, it's the tick vaccines that are mainly the deliveries we do in Vaccines. If you then go to the strategic focuses that we have in this segment, we can really see that the higher NPS is helping us. And it will also help us for the future. We have worked extensively on being close to the customer, emphasizing customer centricity, and building strong partnerships. And this is something that we will continue to do also for the future. Being close to the customer, in combination with high-quality services that we provide and really delivering on time and in full to our customers, is something that will also help us in this segment for the future. One example of the customers with whom we have succeeded is the onboarding process that we have now been conducting for new customers in the distribution segments. We have talked about that for the last six months or so, and we can see now that it's really happening. This is the time period that we normally have from closing a deal until we then start to deliver. I'm really happy to see that we are also utilizing the wholesale segment and advisory services in this segment. So we can see that the new customers are going cross-market presence, but also across the segments that we have. We are also continuing to develop our capabilities and service portfolio for the possible deregulation that we might see coming in Finland. We will be ready for that whenever it comes. Then going to the wholesale segment, in this segment, we have performed the sales of traded goods and over-the-counter medicines like painkillers, as well as parallel trading of medicines, specialized medicines, and advisory services. The net sales in this segment were also growing. It's growing by 9% to €8 million. We could especially see growth in Sweden, and sales in Finland were impacted by the weaker market, some strikes in the retail channel, and some hoarding. At the end of last year, we saw that profitability in this segment declined by 34%, with adjusted EBITDA landing at €2.4 million, and this is mainly due to high operational expenses resulting from planned growth in this segment. The investments we have done are to be able to continue to grow for the future, and it is important that we continue with the growth while also stabilizing the investments for the future. We have also had an unfavorable product mix in this segment that is driving up the costs. If you go down to the strategic parts of this wholesale, these segments, the long-term strategic goals are very much to grow the wholesale business. As we have announced before, the wholesale business has a higher margin compared to the distribution segment. And this is also the segment where we should grow the most. We can see that the portfolio expansion and the collaboration with E-com customers across the market has been proceeding well, and it's important for us to learn from what we’re doing in Sweden in the e-com and also being able to utilize that knowledge in Finland. We have also done a lot of work on the retail channel in Finland, which is building for the future. So we have had a strong focus both on finding new customers on the retail side, as well as expanding the assortments for these customers. If we then go to advisory services, as I mentioned earlier, we have acquired MedInfo. It's a Danish company, but it's also doing business in Norway. So we have really strengthened the Nordic footprint in this area. Uh, and we can also see that in advisory services. We have continued to expand Oriola Insights, and Oriola Insights is a service where we take the digital data that we have in the company and package it especially towards farmers and pharmaceutical companies to make it easier for them to make decisions in their businesses and help them succeed with whatever they do. And this is something that the customers really appreciate, and we can see an increasing demand for this service. With this, we have covered the part of the business side. So I will now let Max in to be able to dive deeper into the Financial Review.

Mats Danielson
11:25 - 22:57

Thank you, Caterina, and good morning. Also from my side, before we jump into the numbers, I will open up a bit on the changes that we have in the financial reporting from this year. Uh, we have not changed the reporting segments. They are still distribution and wholesale. Uh, however, we have some new key financial indicators that we follow and we will also report them to you. First of all, the sales margin is a very important KPI for Oriola to follow. Uh, and the sales margin actually comes from the distribution and service fees that we invoice. It's also the entire portion of the wholesale sale, minus the cost of goods that we earn. And then, of course, it's also the advisory sales. So a combination of these three is the sales margin. Then we have changed from reporting adjusted EBIT to adjusted EBITDA. The reason for that is more or less that we have the ERP treated as a cost during this year, and some other factors affecting it make it easier to follow the EBITDA compared to the adjusted EBIT. We have added free cash flow in the reporting, and on April 1st, we also announced that we had completed the sale of Svensk dos. We have included Svensk dos in the numbers for '24 and Q1 '25, which had a very limited impact on the full year, with 100,000 in '24 and 200,000 plus in '25. If we then move to the numbers, we had a strong organic growth of 8%, and the invoicing grew by 10%. Still, if we look at the net sales growth itself, there's an impact from the customer moving from consignment stock to inventory last year. However, the organic growth was 8%. If we then move to look at the sales margin, the sales margin was driven by the distribution segment. We had growth from 40 million to 41 million, a 4% increase. And we had a small decline in the sales margin on the wholesale side. If we then look at the EBITDA, the reported EBITDA declined from 6.7 million to 6 million. The main reason for that is that we had more adjusting items this year than last year. The adjusting items are mainly related to the new ERP. We had a cost of 1.3 million in quarter one. If we then look at the total adjusted EBITDA, it was 7.7 million compared to 7.5 million. And then we have from Sweden last year in the first quarter, which had a negative result, and a slightly positive result in the first quarter of 2025, which also gives a positive impact. So there was a small decline in adjusted EBITDA compared to last year. Then if we go into details on the adjusted EBITDA, you can see that. Those in Sweden being a part of the distribution segment, if we take that impact from quarter one out, it was, as I said, 500,000 minus last year, and now 200,000 plus. So the impact was 700,000. Then the distribution business itself added 100,000. And then we had a negative result at the EBITDA level in the wholesale segment. And then we had some group items and we ended up at 7.5 million in adjusted EBITDA. If we then move into the segments. As said, we had a good growth of 8%. Organic growth and invoicing grew by 10%. If we look at the adjusted EBITDA in the distribution segment, we had net sales growth, as mentioned, and we achieved a very good product and service mix sold. So, the result was good. Uh, then on the other hand, we had some more costs, uh, for ensuring Oriola's operations were optimal with a stable and predictable volume and workload. In that way, we can be very productive and efficient in our business. And now we had some fluctuations and volatility in customer behavior. So, that gave us additional costs which negatively affected our cost base. And then we also had the Sweden impact. Uh, impact of 700,000 in adjusted EBITDA for the distribution segment. If we look at the wholesale segment, there was a good growth of 9%. Uh, we had especially good growth in Sweden. Uh, the Finnish wholesale was affected by a weaker market. We had customers stockpiling in December, and there was a strike in the retail sector for a few days in quarter one. So, we had actually the first two months that were a bit slower, and then March was already much better. If we look at the adjusted EBITDA, there was a decline mainly related to the product mix and higher operating expenses. Part of those we have planned to invest for growth. But we can see that. The result did not pass through due to the mix and the higher costs than the base earlier. If we then look at the group again, examining the net profit, we can see that the EBITDA was lower than last year, mainly due to the higher costs in the ERP project compared to last year. Uh, we had a. Write down of when we sold the Svensk dos business, there was an impairment write down of 5.7 million in total, which affected the impairments we had. The EBIT was negative. Then we had financial. Financial expenses were lower than last year due to the lower debt level. Then we had a smaller loss in the joint venture with Kronans Apotek. And that was mainly related to real cost savings, but also partly related to some phasing of costs. In the company. But the good development continues. Then if we look at the free cash flow, compared to last year, we had a very good positive change in working capital. So we had a free cash flow of 25 million compared to minus ten million last year. And that, of course, affects the interest. Net interest-bearing debt is 64 million. We have a lower debt level than last year. And the cash and cash equivalents amount to 135 million. Uh, we have a solid financial position. We have quite a lot of non-cash impact from impairments during the last year. And the equity ratio has declined to 14%. But on the other hand, with the good cash flow, the gearing is -48% impacting that. Kronans Apotek reported strong net sales growth, with particularly notable double-digit growth in e-commerce. As said, part of the profitability improvement is related to cost savings partly phasing, but it was still a good quarter for Kronans Apotek. We also had the AGM on the 2nd of April and we have now combined. It was approved to combine the share classes, and that has been done. So now we have only one share class out on the market. We have also refined the Outlook. We say we have now. It's just we are not talking about the Svensk dos anymore. So we have included and expect to include Svensk dos in the numbers for last year and this first quarter. And we expect the EBITDA to increase from the previous year. And in 2024, it was 33.4 million. All right.

Katerina Gabrielson
23:00 - 23:46

Good. Then, going to the key takeaways. And for the key takeaways, these are the three parts that we really would like you to remember. We can see that we have steady progress towards our long-term goals. And we can really see that through the substantial sales growth and the improved sales margin during the first quarter. So this will be like the fundamentals for achieving more sales growth and also margin and profitability for the future. We are now focusing on executing the refined strategy and also being really cost-conscious. So we are focusing on delivering the outlook that you just saw. So that's the three key takeaways that we have. Now, I know that there have been a lot of questions for us.

Dennis O'Neill
23:46 - 24:43

So yes, indeed. Thank you, Katerina and Matz, for your presentations. And as said, we open up now for your questions and please do send them in through the chat to us. And there are quite a lot of questions at the moment. So, I will try to group some of the questions because they are related to, for example, the ERP project and the Oriola Insights service. But let's first focus on the Q1 related questions that we have received. So there is a question about the opex and cost increases. So could you elaborate a little bit more on where those costs are coming from? And also the impact of the strategic investments in the wholesale segment.

Mats Danielson
24:45 - 25:23

Well, at least I can start. I mean, it's a combination of investing in people. It's in wholesale. It's also in the digital part. And those have been planned. Then on the other hand, we have also more costs as said in the business itself. We have had a kind of. Volatility in the ordering pattern. And we have had to put in more people, and it has been a bit unpredictable when the work has been done. So it costs a bit more than expected.

Katerina Gabrielson
25:23 - 25:41

We can also say that when it comes to the wholesale part, it's very much the expansion with business people. So that is also one part of the strategy. And we hadn't done that last year. So when you compare the figures to last year on that part, it's not comparable. It can be important to spell that out also.

Dennis O'Neill
25:42 - 25:58

Good. Thank you. And then, uh, if we think about growth, top-line growth. So could you reflect a little bit on why there is such good growth in Q1?

Katerina Gabrielson
25:59 - 26:45

I can start on that one. Um, if you look at the distribution channel, of course, it's all about a segment. It's, of course, also affected by the market growth, as you mentioned, as you could see in the presentation; Sweden is growing more than Finland. And that is also contributing to our growth in the distribution segment in that aspect. Then of course, in wholesale, we have worked with more customers and channels. So, we are also following the market growth in that area. So following that but also exceeding it, I will say, we are working very much with the customers. So I think from my perspective, it's also like when you can see that you're growing in the customer base and the confidence, and working closer to them. This is one effect that you can see. That's one of the first positive signs, besides the others.

Dennis O'Neill
26:45 - 26:59

Okay. And continuing on the top line growth and basically a little bit on the outlook. So, what kind of growth should we expect throughout the whole of 2025?

Mats Danielson
27:01 - 27:16

We have not lost any customers during quarter one. We have gained a few customers who have started now. So, we expect the growth to continue. On what level? With some uncertainty.

Dennis O'Neill
27:17 - 27:28

Okay, good. And then, uh, a question about the pharmaceutical market situation in Finland specifically. Could you elaborate on that one?

Katerina Gabrielson
27:29 - 28:25

What you can see is, of course, that the pharmaceutical market has been declining now in the first quarter. Um, and also, if I remember correctly, a little bit at the end of last year. Um, normally the market situation can fluctuate a little bit in the pharmaceuticals, but it's also taking off. In the end, we can see that surrounding factors like aging populations and similar influences are affecting in a positive way. So it will come back. We can also see in the pharmaceutical market for quarter one that there was a change in the VAT in Finland. Uh, 1st of January. And that is affecting us because we had some hoarding or bulk buys at the end of last year. This is also affecting the market situation. So I don't, I can't really see that it will continue for the future, but it will stabilize and continue to follow the growth path that we have set out. As I see it, it will stabilize and continue to follow the growth path that we have outlined.

Dennis O'Neill
28:26 - 28:47

Good. Then we have commented about the product mix. Here's a question specifically for the wholesale segment, where we mentioned there was an unfavorable product mix. So can you please elaborate a little bit on this one? And the plans to mitigate this in the future.

Katerina Gabrielson
28:47 - 29:32

If you remember, the wholesale segment and the product part of that one involve traded goods. It's an over-the-counter product. Like painkillers, for example. It's also parallel imported products in Sweden and special license medicines. All these different areas have different kinds of margins. I will not elaborate on that further here and now. But what we can say is that some parts of this have been growing faster and might not have the highest margin. The one has grown the fastest. And of course, that's also our job to balance how we grow this segment and how we then also drive profitability in that area. So that's what's happening here. We can also see in the pharmaceutical market for quarter one that we had a change in the VAT in Finland.

Dennis O'Neill
29:32 - 29:45

We can also see in the pharmaceutical market for quarter one that we had a change in the VAT in Finland. And then, uh, there is, uh, now jumping a little bit. But going back to the operating environment. So can you provide any further details on the potential impacts of the trade war?

Katerina Gabrielson
29:47 - 30:15

I can say that, of course, we are affected, just like every other company in this situation. And of course, there is also this discussion about whether there will be special tolls on medicines and so on. Um, I think that like every company, we need to monitor this situation, especially now in quarter two, and that's what will happen. And how do we mitigate this one? There is an uncertainty, of course, but not more in this company than in other companies. I don't know if you want to add something.

Mats Danielson
30:15 - 30:23

No, I think we are. We are among other companies and experiencing the same challenges and uncertainties.

Dennis O'Neill
30:25 - 30:51

There is an uncertainty, of course, but not more in this company than in other companies. Then a question to you. So sales is not affecting the P&L but rather the balance sheet in receivables and payables. What kind of effect on the equity ratio does this have? Meaning, what would be the balance sheet total if receivables and payables relating to sales were calculated out of the balance sheet?

Mats Danielson
30:52 - 31:20

Well, we have not simulated that. So I cannot give a really straightforward answer. It is affected by quite many factors. If we have, if we have a, uh, we own the inventory. Or if it's consignment stock. So it would be quite an exercise to calculate that because the terms are quite different with the different types of inventory that we have. We haven't calculated what it would be.

Dennis O'Neill
31:22 - 32:01

Okay. So let's move on then to questions relating to the ERP projects. And here I'm trying to group the questions because there are so many detailed ones. So there are questions from a risk management point of view about how we are managing the balance between running the current ERP systems and building/testing the new ones, and continuing with the question about how we will be mitigating the risks once we go live with the ERP.

Katerina Gabrielson
32:05 - 33:51

I can start a little bit. If you look at the ERP project, we refer to it as the ERP project, but it's also a transformation project to really spell that out for us. It's also about having the possibility to align the businesses between the countries, and that's also a bit of what we are doing. So we look at the processes, for example, we can take the inbound processes. How do we work in inbound in the different sites that we have, and how do we then put that into the system later on? And this is work that we are also doing before we start the building. And that means, of course, that there will be changes in how we work as well as changes in the systems. And that's important for you to understand. This is part of the efficiency gain that we will have once we have gone through the project. Some part of this is, of course, something that we can also gain from already beforehand in this one. So we are looking through the processes. Then we are seeing the specific special parts that we have in Sweden and particular parts that we have in Finland. And then utilizing as much commonality as we can. So, this is the work that we have been doing. And now we're moving into the build phase, which is where we currently are. And then, of course, we are now starting to build. And we are doing that in sprints. And we're also testing these kinds of things one by one. And that's in the end, of course, it will be end-to-end testing to make sure that we are as secure as possible when we are going for the first deliveries. We also execute deployment in phases. So we will make a smaller deployment in the beginning, and that will mitigate some of the risk we will face during the deployment. And I know that this is more detailed than we normally disclose. But now I've made that decision. So I think it's good that we communicate this. Do you want to add something?

Mats Danielson
33:51 - 34:18

I think it's important to stress the fact that it's a transformation and a harmonization project, and we will have the same system in both countries. We already have considerable knowledge of the technical system because we currently use it in Finland, although it's an updated version. So we have people who know how to develop this in-house also.

Katerina Gabrielson
34:20 - 34:42

And of course, I know that there are often comments about whether we take into account the knowledge from what happened in 2017 here in Finland. And yes, we do. We are not going to release here. How do we take that knowledge, and of course, how do we mitigate the risk? But there is absolutely risk mitigation and cutover projects in this one also.

Dennis O'Neill
34:43 - 35:16

Then we are observing the special segments that we have in Sweden and the unique parts that we have in Finland. Then we are seeing the special parts that we have in Sweden and special parts that we have in Finland. And then, um, there's a question about KPIs relating to the ERP. So how are we measuring or tracking the success post implementation. And then also relating to this. So how will this ERP project support us in addressing the issues with medicine availability and also to improve customer service KPIs like picking quality. So about measuring the ERP.

Mats Danielson
35:18 - 35:50

Yeah, I mean it's of course easier to improve on one system than to have two or multiple old systems. So. So, I think the quality will, of course, improve. Then, in all aspects, it's easier to drive one system and to have the same KPIs, and of course, we have quite a lot of the same customers in Finland and Sweden. So, so we will be more transparent in our communication and reporting to them by also having the same system.

Dennis O'Neill
35:52 - 36:10

Okay, good. And then, uh, a final question around the ERP. And that's relating to the costs and how we are treating it. Uh, it is either as a CapEx or OpEx. So, would you like to recap on that?

Mats Danielson
36:10 - 36:29

Yeah. Nothing has actually changed from the previous statement that we gave, that most of the cash out will be booked as a cost in the adjusting items. And we report that separately in the income statement and elaborate on that every quarter. What we have.

Dennis O'Neill
36:29 - 36:55

So, all right. Good. So. And then we continue to the next topic where we have, uh, quite a few questions. So it's about the Oriola Insights service that is provided by the advisory business. So, um, there's first a question about the margins and our expectations in revenue terms. So, would you still like to comment on that one? At some level.

Katerina Gabrielson
36:55 - 37:08

At some level, it's the same as when we take into account traded goods and so on. Of course, we're not taking it completely, but you can say overall the advisory services have a margin at a double-digit level. So, this is, of course, following our standard business practices.

Dennis O'Neill
37:09 - 37:16

Good. And, um, any comments on customer feedback relating to Oriola Insights?

Katerina Gabrielson
37:16 - 37:42

That we can take? You can see that, of course, it's quite a new service that we have. But also, as I mentioned earlier in the presentation, we have received quite a lot of positive feedback on this one. And I can also see an increasing demand for this service. And of course, we are developing this both independently and collaboratively with our customers. So I can see both good progress and positive developments. I would say preparation, not protection, but rather preparation for the future.

Dennis O'Neill
37:43 - 37:58

Great. Thank you. And then, uh, there's a question relating to Svensk dos. So, um, and it's here. Uh, so what are you going to do with the money from selling Svensk dos?

Katerina Gabrielson
38:00 - 38:18

I can say it like this: As mentioned earlier, we have ERP projects that need to be paid. Since most of it is opex, we have other things that need to be done. So, um, I'm sure we will use the money in a good way. And of course, hopefully that will also help to pay more dividends in the future.

Mats Danielson
38:18 - 38:20

And invest in the future.

Katerina Gabrielson
38:20 - 38:21

Exactly right.

Dennis O'Neill
38:22 - 38:42

And then, uh, a couple of questions relating to Kronans Apotek. So first, the near-term question. So will the integration-related milestones that have been achieved in Kronans Apotek start to affect integration costs/profitability in the very near term?

Katerina Gabrielson
38:44 - 39:28

Overall, you can say that of course, we have announced a target of 25 million by 2025. And, uh, like we said here also, uh, we are not measuring in the same way now because it's also quite, it's, uh, two and a half years since we did this, uh, joint venture. And it's getting increasingly difficult to define what constitutes real integration. What we can say here is that we can see that the major milestone, especially now merging the companies, was indeed a significant achievement. Um, so with that one, I will say that we haven't been focusing so much right now on the integration costs, and that one, it's more about filling this gap and getting the base business to really deliver where it should be.

Dennis O'Neill
39:30 - 40:00

Good. Thank you. So just a reminder, because there's a lag between the live sending and where we are. So please send in your questions through the chat to us. And um, so another question relating to Kronans Apotek, maybe a little bit on the longer term. So when can we expect to see Kronans Apotek profitable? And what are Oriola's plans for making Kronans Apotek profitable?

Katerina Gabrielson
40:00 - 40:34

We don't usually phrase it in that way. So? So I will not comment exactly on what that is. Of course. It's like I said. Also, last time I was standing here, we expected Kronans Apotek to be more profitable than it is now, and we are doing our best to really make that happen as soon as possible. And that is also something that Kronans is aware of regarding what we will do for the future. We have a long-term commitment. We have a long-term commitment in Kronans Apotek, and that's what we communicate now. And there are no other decisions taken in this company.

Mats Danielson
40:34 - 40:36

And Kronans Apotek is a very important customer to us.

Katerina Gabrielson
40:36 - 40:38

That's true, that's true.

Dennis O'Neill
40:39 - 41:11

Good. And then, uh, for the time being, the last question that we have is relating to sustainability and, uh, the science-based targets that we have submitted for validation. So, um, when do you expect to get the validation and will it influence future infrastructure investments or logistics development? And here, of course, we have already externally communicated that we are also looking into options. So, if you want to comment.

Katerina Gabrielson
41:11 - 42:07

We have, like you said, sent this in, and you never know exactly how long this will take. But I'm expecting, together with Tua, who is responsible for environmental parts, that this will happen. Then during the year and of course, when we have had this improvement, we will continue to execute the plans and also see exactly how we should adjust the plans and how it will affect us. But we are already working on environmental initiatives. And we have received the gold medal from EcoVadis, which we're really proud of. We have also significantly reduced our carbon emissions since 2019; if I remember correctly, we've reduced them by 90%. So we are working steadily on a strong base with environmental parts. It's really important for us and should be a daily part of our business.

Dennis O'Neill
42:09 - 42:43

Great. Thank you. So at the moment there are no further questions in the chat. And I would like to thank everyone for joining us today and also for all the questions. That was really great. And um, and, and our next event, uh, is the publication of the Q2 half-year report on 18th July. And until then, please don't hesitate to reach out to us if you have any further questions that you would like to discuss with us. Thanks, everyone.

Katerina Gabrielson
42:43 - 42:43

Thank you, thank you.

Continue to the webcast
Lundbeck - Præsentation af delårsrapport for Q3 2026
Language: Danish11/12/2026, 12:00 PM
H. Lundbeck A/S ventes at offentliggøre sin delårsrapport for Q3 2026 den 11. november 2026. Dagen efter, den 12. november kl. 13.00, vil Jens Høyer, Vice President & Head of Investor Relations, præsentere resultaterne og svare på spørgsmål fra publikum i et live online event.
Wirtek - Presentation of Q3 2026 Interim Report
Language: English11/12/2026, 10:00 AM
Wirtek is expected to release its Q3 2026 interim report on 11 November 2026. The next day at 11.00 CET, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Rovsing - Præsentation af Interim Management Statement for Q1 2026/27
Language: Danish11/11/2026, 12:00 PM
Rovsing ventes at offentliggøre sin Interim Management Statement for Q1 2026/27 den 10. november 2026. Den 11. november kl. 13.00 vil ledelsen præsentere kvartalets tal, give en status på udviklingen i forretningen samt følge op på de seneste selskabsnyheder. Præsentationen efterfølges af en Q&A-session.
DADC - Præsentation af handelsopdatering for Q3 2026
Language: Danish11/5/2026, 8:30 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Danish Aerospace and Defence Company (DADC) ventes at offentliggøre sin handelsopdatering for 3. kvartal 2026 den 4. november 2026. Dagen efter, den 5. november kl. 09.30, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
Boozt AB, Audiocast, Q3'26
Language: English11/3/2026, 8:30 AM
Herman Landin Thank you and good morning to all. Welcome to our Q3 2026 presentation. So, let's turn to the first slide, please. We will follow our usual agenda. I'll take you through the highlights a…
NORDEN – Presentation of Q3 2026
Language: English10/29/2026, 9:30 AM
NORDEN is expected to release its Q3 2026 results on 29th October 2026. The same day at 10.30am, management will present the results in an online event followed by a Q&A.
Agillic – Præsentation af kvartalsrapporten for Q3 2026
Language: Danish10/22/2026, 8:00 AM
Du kan allerede nu tilmelde dig eventet og sende dine spørgsmål ind. Du behøver ikke at deltage live for at sende spørgsmål til præsentationen. Agillic offentliggør kvartalsrapporten for Q3 2026 den 22. oktober 2026. Samme dag kl. 10:00 vil selskabets CEO Christian Samsø præsentere resultaterne, gennemgå forventningerne til resten af 2026, give en opdatering på markedsforholdene og besvare spørgsmål ved et online live-event.
Nordea third-quarter results 2026
Language: English10/15/2026, 8:00 AM
Head of Investor Relations Good morning and welcome to Nordea's third-quarter 2026 results. Nordea's third-quarter 2026 results. I am your Head of Investor Relations. As usual, we will start with the…
GreenMobility - Presentation of the Q3 2026 Trading Statement
Language: English10/14/2026, 11:00 AM
GreenMobility is expected to release its Q3 2026 Trading Statement on 8 October 2026. On 14 October at 13:00 CEST, CEO Kasper Gjedsted will present the figures and answer questions in a live online event.
Rovsing – Præsentation af årsrapport 2025/26
Language: Danish9/28/2026, 9:00 AM
Rovsing ventes at offentliggøre årsrapporten for regnskabsåret 2025/26 den 25. september 2026. Den 28. september kl. 11.00 vil ledelsen præsentere årets resultater, give en status på udviklingen i forretningen samt kigge frem mod 2026/27. Præsentationen efterfølges af en Q&A-session
Danish Aerospace and Defence Company – Præsentation af H1 2026 resultater
Language: Danish8/25/2026, 8:00 AM
Danish Aerospace and Defence Company (DADC) ventes at offentliggøre selskabets rapport for H1 2026 den 24. august 2026. Dagen efter, den 25. august kl. 10.00, vil selskabets CEO, Thomas A.E. Andersen, præsentere resultaterne samt svare på spørgsmål i et online live-event.
North Media – Præsentation af regnskabet for 2. kvartal 2026
Language: Danish8/21/2026, 12:00 PM
Tilmeld dig North Media’s præsentation af regnskabet for 2. kvartal 2026 – fredag d. 21. august 2026 kl. 14.00. Se med når ledelsen i North Media gennemgår kvartalsregnskabet der offentliggøres dagen før, og hvordan første halvår af 2026 er forløbet, samt svarer på spørgsmål.
Wirtek – Presentation of Q2 2026 Interim Report
Language: English8/14/2026, 9:00 AM
Wirtek is expected to release its Q2 2026 interim report on 12 August 2026. Friday 14 August at 11.00 CEST, CEO Michael Aaen and CFO Mads Greiffenberg will present the results in a virtual live event with a Q&A session.
Boozt AB, Audiocast, Q2'26
Language: English8/14/2026, 7:30 AM
Herman Thank you. Good morning to all, and welcome to our Q2 2026 webcast. So let's turn to the first slide, the agenda for today's presentation. We will follow our usual agenda. I'll take you through…
NORDEN – Presentation of the quarterly report for Q2 2026
Language: English8/13/2026, 8:30 AM
NORDEN is set to release its quarterly report for Q2 2026 on the morning of Thursday 13 August 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q2'26
Language: English8/12/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on second quarter 2026 results. My name is Mirko Hurmerinta, the interim Head of IR at Sampo. I am joined on the c…
Nordea half-year results 2026 webcast
Language: English7/16/2026, 8:00 AM
Ilkka Good morning and welcome to Nordea's second quarter 2026 results. I am Ilkka, Head of Investor Relations. As usual, we'll start with the presentation by Group CEO Frank Vang-Jensen, followed by…
NORDEN – Presentation of the quarterly report for Q1 2026
Language: Danish5/6/2026, 8:30 AM
NORDEN is set to release their quarterly report for Q1 2026 on the morning of Wednesday 6 May 2026. On the same day at 10:30 AM, we are pleased to invite you to a presentation of the financial results with CEO Jan Rindbo and CFO Martin Badsted, who will also answer questions from the audience.
Sampo Oyj, Audiocast, Q1'26
Language: English5/6/2026, 7:30 AM
Mirko Hurmerinta Good morning, everyone, and welcome to Sampo Group's conference call on first quarter 2026 results. My name is Mirko Hurmerinta and I am the interim Head of Investor Relations at Samp…
Boozt AB, Audiocast, Q1'26
Language: English4/24/2026, 7:30 AM
Herman Good morning and welcome to our presentation of our Q1 2026 report. Let's just go to the agenda slide. We will have the usual agenda for the presentation. And I will present the highlights of t…